Please assess the completion status of the following clinical trial:

Trial Title: An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 80 years old~* Females must be non-pregnant, non-lactating, and either be post-menopausal for at least 12 months, have documentation of irreversible surgical sterilization, or confirm the use of one of the acceptable contraceptive methods.~* Males must agree to avoid fathering a child and agree to use an appropriate method of contraception~* Chronic maintenance hemodialysis 3x/week for at least 3 months~* Kt/V ≥ 1.3 at most recent measurement prior to screening~* Prescribed and taking at least 3 doses of phosphate binder per day~* Serum phosphate levels should be between 4.0 and 7.0 mg/dL (inclusive) at screening~* For randomization in the study, after 1 week wash-out of phosphate binders, subjects must have serum phosphate level of at least 9 mg/dL but below 10 mg/dL and have had an increase of at least 1.5 mg/dL versus pre-wash out value~* For randomization in the study, after 2 or 3 weeks wash-out of phosphate binders, subjects must have serum phosphate level of at least 6 mg/dL but below 10 mg/dL and have had an increase of at least 1.5 mg/dL versus pre-wash out value~Exclusion Criteria:~* Severe hyperphosphatemia defined as \>10 mg/dL on Phosphate-binders at any time point during clinical routine monitoring for the 3 preceding months before screening~* Serum parathyroid hormone \>1200 pg/mL~* Persistent metabolic acidosis defined as serum carbon dioxide \<18 mmol/L from two consecutive measurements during screening and washout periods~* Clinical signs of hypovolemia at randomization~* History of inflammatory bowel disease (IBD) or diarrhea predominant irritable bowel syndrome (IBS-D)~* Scheduled for living donor kidney transplant, change to peritoneal dialysis, home HD or plans to relocate to another center during the study period~* Diarrhea or loose stools during the week before randomization defined as BSFS ≥ 6 and frequency ≥ 3 for 2 or more days~* Any evidence of or treatment of malignancy within one year, excluding non-melanomatous malignancies of the skin~* Positive serology with evidence of significant hepatic impairment or WBC elevation according to the Investigator~* Life expectancy \< 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 3mg BID (Type: EXPERIMENTAL): Tenapanor, 3mg BID (6mg total)
- 10mg BID (Type: EXPERIMENTAL): Tenapanor, 10mg BID (20mg total)
- Dose Titration (Type: EXPERIMENTAL): Tenapanor, patients start at 30mg BID and can down titrate weekly to 20, 15, 10, and 3mg BID, sequentially based on a GI tolerability question
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).